157 related articles for article (PubMed ID: 15814651)
21. Synthesis and antitumor evaluation of a highly potent cytotoxic DNA cross-linking polyamine analogue, 1,12-diaziridinyl-4,9-diazadodecane.
Li Y; Eiseman JL; Sentz DL; Rogers FA; Pan SS; Hu LT; Egorin MJ; Callery PS
J Med Chem; 1996 Jan; 39(1):339-41. PubMed ID: 8568824
[TBL] [Abstract][Full Text] [Related]
22. Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1.
Danson SJ; Johnson P; Ward TH; Dawson M; Denneny O; Dickinson G; Aarons L; Watson A; Jowle D; Cummings J; Robson L; Halbert G; Dive C; Ranson M
Ann Oncol; 2011 Jul; 22(7):1653-1660. PubMed ID: 21378203
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
[TBL] [Abstract][Full Text] [Related]
24. Chloroacetaldehyde: mode of antitumor action of the ifosfamide metabolite.
Brüggemann SK; Radike K; Braasch K; Hinrichs J; Kisro J; Hagenah W; Peters SO; Wagner T
Cancer Chemother Pharmacol; 2006 Feb; 57(3):349-56. PubMed ID: 16133533
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
26. Melphalan-induced DNA damage in p53(+/-) and wild type mice analysed by the comet assay.
Cordelli E; Cinelli S; Lascialfari A; Ranaldi R; Pacchierotti F
Mutat Res; 2004 Jun; 550(1-2):133-43. PubMed ID: 15135647
[TBL] [Abstract][Full Text] [Related]
27. pH dependence of mitomycin C-induced cross-linking activity in EMT6 tumor cells.
Kennedy KA; McGurl JD; Leondaridis L; Alabaster O
Cancer Res; 1985 Aug; 45(8):3541-7. PubMed ID: 3926302
[TBL] [Abstract][Full Text] [Related]
28. Development and validation of a sensitive solid-phase extraction and high-performance liquid chromatographic assay for the novel bio-reductive anti-tumor agent RH1 in human and mouse plasma.
Khan P; Abbas S; Hargreaves RH; Caffrey R; Megram V; McGown A
J Chromatogr B Biomed Sci Appl; 1999 Jun; 729(1-2):287-95. PubMed ID: 10410954
[TBL] [Abstract][Full Text] [Related]
29. DNA strand scission and cross-linking by diaziridinylbenzoquinone (diaziquone) in human cells and relation to cell killing.
Szmigiero L; Erickson LC; Ewig RA; Kohn KW
Cancer Res; 1984 Oct; 44(10):4447-52. PubMed ID: 6467204
[TBL] [Abstract][Full Text] [Related]
30. Cytotoxicity of RH1: NAD(P)H:quinone acceptor oxidoreductase (NQO1)-independent oxidative stress and apoptosis induction.
Tudor G; Alley M; Nelson CM; Huang R; Covell DG; Gutierrez P; Sausville EA
Anticancer Drugs; 2005 Apr; 16(4):381-91. PubMed ID: 15746574
[TBL] [Abstract][Full Text] [Related]
31. Quinone-induced DNA damage and its relationship to antitumor activity in L5178Y lymphoblasts.
Begleiter A; Blair GW
Cancer Res; 1984 Jan; 44(1):78-82. PubMed ID: 6537800
[TBL] [Abstract][Full Text] [Related]
32. Unsymmetrical DNA cross-linking agents: combination of the CBI and PBD pharmacophores.
Tercel M; Stribbling SM; Sheppard H; Siim BG; Wu K; Pullen SM; Botting KJ; Wilson WR; Denny WA
J Med Chem; 2003 May; 46(11):2132-51. PubMed ID: 12747786
[TBL] [Abstract][Full Text] [Related]
33. Formation of DNA interstrand cross-links as a marker of Mitomycin C bioreductive activation and chemosensitivity.
Volpato M; Seargent J; Loadman PM; Phillips RM
Eur J Cancer; 2005 Jun; 41(9):1331-8. PubMed ID: 15869876
[TBL] [Abstract][Full Text] [Related]
34. Induction of p53-mediated senescence is essential for the eventual anticancer therapeutic effect of RH1.
Jung J; Song DY; Hwang JJ; Park HJ; Lee JS; Song SY; Jeong SY; Choi EK
Arch Pharm Res; 2019 Sep; 42(9):815-823. PubMed ID: 30879173
[TBL] [Abstract][Full Text] [Related]
35. DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.
Singleton RS; Guise CP; Ferry DM; Pullen SM; Dorie MJ; Brown JM; Patterson AV; Wilson WR
Cancer Res; 2009 May; 69(9):3884-91. PubMed ID: 19366798
[TBL] [Abstract][Full Text] [Related]
36. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
Bao R; Lai CJ; Qu H; Wang D; Yin L; Zifcak B; Atoyan R; Wang J; Samson M; Forrester J; DellaRocca S; Xu GX; Tao X; Zhai HX; Cai X; Qian C
Clin Cancer Res; 2009 Jun; 15(12):4046-57. PubMed ID: 19509149
[TBL] [Abstract][Full Text] [Related]
37. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen.
Yip KW; Mao X; Au PY; Hedley DW; Chow S; Dalili S; Mocanu JD; Bastianutto C; Schimmer A; Liu FF
Clin Cancer Res; 2006 Sep; 12(18):5557-69. PubMed ID: 17000693
[TBL] [Abstract][Full Text] [Related]
38. Novel DNA-directed alkylating agents: design, synthesis and potent antitumor effect of phenyl N-mustard-9-anilinoacridine conjugates via a carbamate or carbonate linker.
Kapuriya N; Kapuriya K; Dong H; Zhang X; Chou TC; Chen YT; Lee TC; Lee WC; Tsai TH; Naliapara Y; Su TL
Bioorg Med Chem; 2009 Feb; 17(3):1264-75. PubMed ID: 19124250
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
Zhang Y; Ma Y; Lu HP; Gao JH; Liang CS; Liu CZ; Zou JT; Wang HQ
Chin Med J (Engl); 2008 Nov; 121(22):2284-9. PubMed ID: 19080333
[TBL] [Abstract][Full Text] [Related]
40. Cytotoxicity of the bioreductive agent RH1 and its lack of interaction with radiation.
Kim JY; West CM; Valentine H; Ward TH; Patterson AV; Stratford IJ; Roberts SA; Hendry JH
Radiother Oncol; 2004 Mar; 70(3):311-7. PubMed ID: 15064018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
